How Advances in Quantitative Imaging Can Affect Companies and Stocks

Stereology rarely appears in an earnings presentation or stock screener, yet the scientific methods behind it sit close to several industries that investors follow closely. Stereology uses statistical sampling and geometrical principles to estimate three dimensional quantities such as cell number, tissue volume, surface area and fibre length from sampled sections or images. In laboratories, those measurements can help researchers turn microscopy into quantitative data rather than relying on visual impressions alone. In commercial terms, that creates demand for microscopes, imaging systems, software, pathology services and research workflows capable of producing accurate and reproducible measurements.

The investor connection is therefore indirect. There is no large public “stereology sector” in the same sense as semiconductors or pharmaceuticals. Progress in stereological measurement tends to appear inside broader areas such as digital pathology, neuroscience, drug safety testing, microscopy, automated image analysis and materials characterisation. The companies that can benefit are usually selling the instruments, software or services required to perform those measurements, or using better quantitative biology to make research decisions faster.

That distinction matters. Investors should not assume that a breakthrough in stereological methodology automatically creates a large new market. The more useful question is whether the advance reduces labour, increases throughput, improves reproducibility or enables measurements that were previously too slow or expensive to perform routinely.

Why Stereology Matters Commercially

Traditional stereology is labour intensive. A trained researcher may need to select tissue sections systematically, identify a region of interest, position counting frames and record cells or structures according to defined inclusion rules. The method can produce strong quantitative estimates, but manual work limits throughput. This is one reason stereology historically fitted academic neuroscience and pathology research better than very high volume industrial workflows.

Automation changes that economic equation. Research published on the automatic optical fractionator found that automated stereological cell counting could be substantially faster than manual optical fractionator methods while reducing observer subjectivity. The study reported an eight to tenfold speed improvement under its experimental conditions. The published automatic optical fractionator research demonstrates why automation matters commercially: the value is not only better counting, but more measurements per scientist and more consistent analysis across larger experiments.

For investors, throughput is often more financially important than the scientific label attached to the method. If automated microscopy and analysis allow laboratories to process more samples without increasing labour at the same rate, the technology can justify capital expenditure. Vendors can sell higher value instruments and software, while laboratories can spread fixed costs over more research projects.

The same economic logic appears in digital pathology. Moving slides from physical microscopes into digital files allows analysis to be repeated, shared and automated. Stereological principles become part of a broader quantitative workflow rather than a separate specialist technique.

Microscopy Companies Are the Most Direct Public-Market Exposure

Scientific instrument companies are among the clearest public-market beneficiaries of progress in quantitative microscopy. Stereology depends on acquiring images with sufficient resolution, accurate positioning and appropriate depth information. As research moves from simple two dimensional observation toward automated three dimensional analysis, laboratories require better optics, motorised stages, cameras, data processing and software.

Danaher provides one example through Leica Microsystems. Danaher’s Leica Microsystems business develops microscopes and scientific instruments across life science, medical and industrial markets. Danaher states that Leica joined its portfolio in 2005. Modern Leica systems combine microscopy with cameras, software, automation and machine learning rather than treating the microscope as an isolated optical device.

That matters because contemporary stereological work is increasingly tied to integrated imaging. A laboratory performing systematic sampling can use motorised stages to move between predefined fields rather than positioning every field manually. Z stacks can provide optical depth for three dimensional counting. Software can record sampling locations and automate parts of segmentation or classification.

Danaher’s commercial exposure is much broader than stereology, which is exactly why investors need to avoid overstating the connection. Stereological research contributes to demand for imaging technology, but it is one application among cancer research, neuroscience, cell biology, medical inspection and industrial microscopy. The investment question is therefore whether quantitative imaging is increasing the usefulness and replacement value of Leica’s broader microscopy platform, not how much revenue can be labelled “stereology.”

Danaher Shows How Imaging Can Become a Platform Rather Than an Instrument

The shift from standalone microscopes toward connected imaging platforms can change the economics of scientific equipment. Leica’s Mica system, for example, combines widefield and confocal imaging with automated acquisition and three dimensional analysis capabilities. Danaher’s current Mica product material describes automated imaging, Z stacking, three dimensional analysis, deconvolution, time lapse work and other functions within one environment.

For investors, this kind of product design can matter more than a small improvement in optical resolution. A laboratory purchasing an integrated platform may also require software, service contracts, cameras, accessories and future upgrades. The resulting customer relationship can have more recurring economics than a simple equipment sale.

Danaher also owns Leica Biosystems, which operates in pathology rather than research microscopy alone. In July 2026, Danaher disclosed that Leica Biosystems intended to acquire StatLab, a histology-products company that Danaher said generated about $250 million of 2025 revenue and had more than 85% recurring revenue. Danaher’s second-quarter 2026 results show how pathology workflows can pull instrument companies toward consumables and recurring laboratory revenue.

The investor implication is broader than stereology. Quantitative tissue analysis becomes more valuable when the vendor participates in multiple parts of the workflow, from sample preparation to imaging and analysis.

Thermo Fisher Connects Quantitative Imaging With a Much Larger Research Business

Thermo Fisher Scientific offers another route into the theme. The company is far too large and diversified to describe as a stereology investment, but its electron microscopy, analytical imaging and life science products place it inside the infrastructure required for quantitative biological and materials research.

Thermo Fisher has increasingly discussed artificial intelligence in image-analysis workflows. In June 2026, the company described machine learning and deep learning being used to improve segmentation and quantitative analysis of microscopy images, reducing manual effort when researchers process complicated biological datasets. Thermo Fisher’s 2026 discussion of AI image analysis reflects the broader movement from acquiring images toward extracting repeatable measurements from them.

From an investor perspective, that transition can increase the value of the instrument stack. The microscope produces the raw data, but software and analysis determine how useful the data becomes. Customers interested in cell counts, spatial relationships, morphology or three dimensional structure may be willing to pay for systems that reduce the number of manual steps between image acquisition and scientific result.

Thermo Fisher’s scale also demonstrates why investors should measure financial materiality. Its 2025 revenue was $44.6 billion, with Analytical Instruments generating about $7.6 billion. Thermo Fisher’s 2025 results make clear that one stereology-related application cannot drive the whole company. The relevant thesis would need to concern a much larger trend toward quantitative and automated imaging.

Bruker Offers More Concentrated Exposure to Advanced Imaging

Bruker sits closer to advanced scientific imaging than many diversified laboratory companies. Its fluorescence microscopy portfolio includes multiphoton systems, super-resolution microscopy, light-sheet imaging, quantitative phase imaging, miniscopes and spatial biology tools. Bruker’s fluorescence microscopy portfolio explicitly targets neuroscience, oncology, immunology and complex tissue research.

This makes Bruker interesting to investors following the technical direction of stereology because modern quantitative biology increasingly involves thick samples, organoids and three dimensional models rather than simple thin sections. Stereological sampling remains relevant, but image acquisition is moving toward richer volumetric datasets.

Bruker’s 2026 materials show this progression clearly. Its automated imaging and light-sheet workflows combine high-content microscopy with data processing and storage, while the company is promoting 3D imaging for cleared organs and biological models. Bruker’s 2026 automated imaging material describes automated acquisition, light-sheet imaging and infrastructure for handling large image datasets.

The commercial opportunity arises when a scientific method creates data volumes that ordinary laboratory workflows cannot manage comfortably. Better microscopes alone do not solve that problem. Researchers need acquisition, storage, computation and analysis. Companies able to sell several parts of that chain can capture more spending from each laboratory.

Digital Pathology Is Where Stereology Meets a Much Larger Clinical Market

Stereology began largely as a way to extract unbiased quantitative measurements from sampled tissue. Digital pathology expands the same principle into a far larger clinical and pharmaceutical environment. Slides are scanned at high resolution, stored digitally and analysed by pathologists or algorithms rather than being viewed only through conventional microscopes.

The FDA defines digital pathology around the scanning, visualisation, analysis, storage and interpretation of tissue slides. Its Digital Pathology Program is working on issues such as image quality, segmentation performance, AI reproducibility and generalisation. The regulator notes that whole-slide imaging became an authorised clinical device category in the United States in 2017.

For investors, regulatory work is relevant because clinical pathology has a much higher commercial bar than academic image analysis. A research laboratory can test experimental software relatively freely. A diagnostic system used to influence patient care needs much stronger validation.

Stereological progress contributes to this market by improving the quantitative logic behind tissue measurement, but the investment opportunity is larger than stereology. Digital pathology companies are trying to convert glass-slide workflows into data platforms that support remote review, algorithmic analysis, biomarker measurement and eventually more personalised treatment decisions.

Roche Shows Why Large Diagnostics Companies Care About Digital Tissue Data

Roche is one of the clearest examples of a large healthcare company treating digital pathology as strategically important. Its 2025 annual report discusses the use of digital tools and algorithms to make pathology analysis more precise and less dependent on subjective visual interpretation. Roche’s 2025 annual report presents digital pathology as part of the company’s broader diagnostics strategy.

The company went further in May 2026 by announcing a definitive agreement to acquire PathAI, a business specialising in AI-driven pathology software. Roche said the acquisition would combine PathAI’s image management and AI capabilities with Roche’s existing digital pathology and companion-diagnostics activities. Roche’s PathAI announcement specifically cited laboratory efficiency, biomarker discovery and clinical therapy development among the expected benefits.

The investor relevance is not that PathAI is performing classical stereology on every slide. The connection is methodological. Stereology established disciplined ways to turn sampled tissue into quantitative measurements. AI pathology extends quantitative tissue analysis across much larger datasets.

If digital pathology increasingly produces validated measurements that influence drug selection, companion diagnostics and clinical workflows, the commercial value shifts from the microscope alone toward an integrated diagnostics platform containing scanners, assays, algorithms and data management.

Better Quantification Can Affect Pharmaceutical Development Indirectly

Drug developers can benefit from stereological progress even when they never sell a stereology product. Preclinical research frequently requires scientists to determine whether a treatment changes cell numbers, tissue structure or pathological lesions. In neuroscience, researchers may need to quantify neuronal loss. Toxicology studies can require detailed evaluation of tissue changes after drug exposure.

The FDA’s guidance on histopathology in biomarker qualification emphasises scientifically rigorous generation of histopathological data when tissue changes are being used to support biomarker development. The regulator’s current biomarker programme also recognises histologic and imaging characteristics as potential biomarkers when properly defined and validated.

The financial effect on a drug company is indirect but potentially valuable. More reproducible measurements can improve the information available when deciding whether to continue a development programme. A weak candidate identified earlier can be stopped before expensive later-stage trials, while a genuine treatment effect may be detected more confidently.

Investors should still avoid turning this into a simplistic argument that better stereology means more approved drugs. Drug development fails for many reasons, and quantitative histology addresses only part of the process. The economic advantage lies mainly in reducing measurement uncertainty.

Contract Research Companies Can Monetise Quantitative Pathology More Directly

Contract research organisations can capture revenue from advances in quantitative pathology more directly because pharmaceutical and biotechnology companies outsource preclinical studies, toxicology and tissue analysis to them.

Charles River Laboratories provides a current example. In May 2026, the company announced an expanded AI-enabled digital pathology workflow that it said could remove at least one week from standard pathology timelines while maintaining Good Laboratory Practice requirements. Charles River’s 2026 digital pathology announcement describes integrated histology systems, AI-assisted slide quality control and validated digital pathology reviews.

Charles River also offers AI-assisted quantitative image analysis across immunofluorescence, brightfield and electron microscopy. Its image-analysis services are aimed at drug discovery, efficacy testing and safety assessment.

For an investor, this is a clearer business model than trying to estimate how many stereological measurements a pharmaceutical company performs internally. Charles River can charge clients for the service itself. If automated pathology reduces turnaround time and increases the number of studies each pathologist can support, the economic benefit can appear through capacity utilisation, labour efficiency and client retention.

The risk is that technology also commoditises parts of the service. Automation creates value for established providers, but software can also make it easier for customers or competitors to perform some measurements internally.

Neuroscience Is One of the Strongest Scientific Drivers

Stereology has an especially close relationship with neuroscience. Counting neurons accurately is difficult because cells vary in size and can appear in several tissue sections. The optical fractionator was developed to estimate total cell numbers without relying on assumptions about cell shape or size. The original method combined systematic sampling with a three dimensional counting probe and became widely used in quantitative neuroanatomy. The foundational optical fractionator research remains an important reference for the field.

The commercial connection becomes stronger as neuroscience moves toward higher resolution and more automated imaging. Bruker markets multiphoton systems, miniscopes and spatial biology products for neural research, while Leica microscopy systems are used in neuroscience and neurodegenerative disease studies. These platforms allow researchers to examine structure and function at scales that older manual stereology systems could not handle efficiently.

For drug investors, better quantitative neuroscience can improve preclinical measurement in areas such as Parkinson’s disease, Alzheimer’s disease, traumatic brain injury and neurotoxicity. Researchers can estimate neuronal survival rather than relying on visual descriptions of tissue damage.

The effect on any individual biotechnology company’s valuation remains secondary to clinical efficacy, safety, financing and regulatory results. Stereology can improve measurement. It cannot rescue a therapy that does not work.

Organoids and 3D Biology Expand the Measurement Problem

One of the more interesting developments for investors is the move from flat cell cultures toward organoids, spheroids and other three dimensional biological models. These systems attempt to reproduce more of the architecture found in real tissues, which can make them more biologically informative but considerably harder to measure.

Traditional two dimensional cell counting methods become less useful when cells are distributed through a thick three dimensional structure. Researchers need imaging systems capable of penetrating the sample, collecting volumetric data and measuring spatial relationships.

Bruker’s 2026 organoid work highlights light-sheet, multiphoton and atomic force microscopy for studying structure, disease processes and treatment response in complex 3D models. Bruker’s 2026 organoid imaging programme illustrates how imaging vendors are positioning around this transition.

This is closely related to stereology even when researchers use newer computational approaches. The underlying problem remains familiar: how do you estimate biologically meaningful three dimensional quantities from a manageable amount of imaging data?

If organoid use expands in drug discovery, vendors offering fast 3D imaging and quantitative analysis can benefit even if customers no longer describe the workflow as stereology.

New Drug-Development Methods Could Change the Value of Quantitative Imaging

The regulatory movement toward new approach methodologies adds another reason for investors to follow quantitative tissue analysis. In March 2026, the FDA published draft guidance on the use of new approach methodologies in drug development, encouraging validated methods that can improve human relevance while reducing reliance on traditional animal testing. The FDA’s 2026 NAM guidance includes a framework for validating new methods used in regulatory submissions.

This does not make stereology a replacement for animal testing. It does create a broader environment in which organoids, advanced imaging, digital pathology and quantitative tissue measurements can become more valuable parts of drug-development evidence.

Investors following instrument companies should watch whether these methods move from specialist academic use into routine regulated workflows. That transition is commercially important because regulated processes tend to demand validated equipment, repeatable software and documented procedures. Once a workflow becomes embedded in standard laboratory operations, replacement cycles and service revenue can become more predictable.

The important signal is therefore adoption, not publication count. An interesting stereological technique may remain commercially irrelevant for years if laboratories cannot validate, automate or scale it.

Materials Science Creates Another Route Into Stereological Measurement

Stereology is not confined to medicine. The same geometrical principles are used when scientists estimate grain size, particle distributions, porosity, phase fractions and internal surfaces within materials.

This creates connections to batteries, semiconductors, metals, polymers and nanotechnology. The exact analytical techniques may include electron microscopy, X-ray microscopy, atomic force microscopy and spectroscopy rather than biological light microscopy.

Thermo Fisher’s materials science systems combine microscopy with elemental and structural analysis. Its transmission electron microscopy tools can produce quantitative chemical information at very small scales, while tomography can reconstruct three dimensional materials from multiple viewing angles. Thermo Fisher’s materials-science microscopy resources show applications ranging from battery research to nanoparticle analysis.

Bruker similarly markets 3D X-ray microscopy, atomic force microscopy and microanalysis products across materials and semiconductor research. Its 2026 microscopy programme covers applications in semiconductors, polymers and materials science alongside life-science work.

For investors, this diversification can reduce dependence on one research cycle. A microscopy technology developed for biology may also find demand in advanced manufacturing or materials characterisation.

Artificial Intelligence Changes the Economics More Than the Mathematics

AI does not eliminate the sampling principles that make stereology useful. It changes the cost of applying quantitative measurement.

Manual cell classification is slow because a human observer has to inspect each field. Machine-learning systems can segment objects across thousands of images far faster, provided that the model performs reliably on the relevant tissue and imaging conditions. This creates the possibility of applying quantitative morphology to much larger studies.

Danaher describes AI-enabled image analysis as a way of reducing subjectivity and extracting patterns from microscopy datasets. Thermo Fisher similarly discusses AI for segmentation and quantitative analysis, while Charles River is deploying AI across preclinical pathology workflows. These companies are approaching the same commercial problem from different positions: instrument manufacturing, laboratory software and outsourced research services.

The investor should focus on where the economic value accumulates. If AI turns image analysis into inexpensive software, some traditional manual services may face pricing pressure. If proprietary data, validated workflows and integrated hardware create barriers to entry, established vendors may capture more value.

The presence of AI itself is not enough. Competitive advantage comes from workflow integration, regulatory validation, installed base and customer switching costs.

Automation Can Increase the Total Market Even When It Reduces Labour

Automation often looks threatening to businesses that sell laboratory services because fewer human hours are required per sample. The opposite outcome is also possible.

Lowering the cost of a measurement can increase how often researchers use it. A laboratory that previously counted neurons manually in a small subset of experiments may perform quantitative analysis routinely once acquisition and segmentation become automated. Pharmaceutical companies may analyse more tissue endpoints if the marginal labour requirement falls.

This effect matters for instrument and software vendors because the number of measurements can increase faster than the labour required for each measurement decreases. Large datasets also create secondary demand for storage, computing and image-management software.

The automatic optical fractionator research offers a useful example. Faster cell counting does not mean the market for cell counting disappears. It can allow researchers to increase sample sizes, analyse more regions and run experiments that would previously have required too much manual work.

Investors should therefore avoid assuming automation is either automatically positive or negative. The better question is whether it expands usage enough to offset lower labour intensity and which company captures the resulting spending.

Scientific Validation Remains a Commercial Barrier

One of the most important constraints on quantitative imaging is validation. An algorithm that works well on one dataset may perform poorly when staining, scanner type or tissue preparation changes.

The FDA’s digital pathology programme explicitly identifies reproducibility, interoperability and AI generalisation as areas requiring further regulatory science. It is developing methods to evaluate scanners, segmentation performance and the relationship between technical image quality and diagnostic results. The FDA digital pathology programme shows that image digitisation does not automatically create clinically trustworthy data.

This creates both a barrier and an opportunity. Companies capable of validating an end-to-end workflow can build stronger positions than software vendors supplying an isolated algorithm. Regulatory requirements can slow adoption, but once a system becomes embedded in a validated laboratory process, replacing it can become difficult.

For investors, this means apparently slower companies are not always technologically behind. In pathology and drug development, reliability, documentation and repeatability can be worth more than rapidly releasing experimental features.

Better Stereology Does Not Automatically Mean Higher Pharmaceutical Valuations

Investors should be careful when translating scientific progress into stock-market conclusions. A biotechnology company may use excellent stereological analysis and still fail because its drug does not produce sufficient clinical benefit. A pharmaceutical company may save time in preclinical analysis without the saving being large enough to affect group earnings materially.

The financial importance depends on where stereology sits in the company’s economics. For a microscope manufacturer, quantitative imaging can create product demand directly. For a pathology-services company, it can affect utilisation and turnaround time. For a drug developer, it is usually an enabling research tool buried inside a much larger programme.

This distinction prevents investors from confusing scientific importance with revenue importance. A laboratory technique can be indispensable to a research project while representing only a tiny percentage of the supplier’s sales.

The same issue appears with scientific instruments. Thermo Fisher and Danaher sell into many research markets. An investor needs evidence that advanced imaging is becoming financially material within the relevant segment rather than assuming every scientific publication using microscopy contributes meaningfully to valuation.

Investors Should Watch Adoption Rather Than Scientific Excitement

One practical way to analyse the theme is to follow movement from manual methods toward routine automated workflows.

A research paper demonstrating a faster stereological technique is the beginning, not the commercial endpoint. The next questions concern compatibility with standard microscopes, reproducibility between laboratories, software integration and whether pharmaceutical or clinical users are willing to validate the system.

Installed base matters because researchers often remain within familiar instrument and software families. A vendor with thousands of microscopes already operating in laboratories can potentially sell analysis upgrades into existing customers. Service networks matter because high-value laboratory instruments require maintenance. Software can add recurring revenue where customers previously purchased mainly hardware.

Company commentary can reveal whether these trends are translating into commercial behaviour. Investors can use research sites such as Investing.co.uk when reviewing stocks, markets and investment products, while company filings and investor-relations material should remain the primary source for revenue, margins and segment performance.

Stereology should therefore act as one research lens rather than a reason to buy a stock by itself.

The Most Obvious Beneficiaries May Not Be the Companies Doing the Science

A recurring pattern in scientific investing is that the suppliers of research tools can have clearer economics than the companies attempting to turn scientific discoveries into therapies.

A biotechnology company may spend hundreds of millions developing one drug that eventually fails. A microscopy company can sell equipment to hundreds of biotechnology companies working on unrelated drugs. A contract research company can earn revenue from studies whether the customer’s final therapy succeeds or fails, provided research spending continues.

This “picks and shovels” logic applies reasonably well to stereology. Danaher, Thermo Fisher and Bruker sell research technology across many scientific programmes. Charles River sells research services. Roche participates both as a pharmaceutical company and as a diagnostics supplier.

The advantage is diversification across experiments. The disadvantage is dilution of the theme. Quantitative imaging may grow rapidly without representing enough revenue to transform a large diversified company’s earnings.

Investors therefore need to decide whether they want direct but smaller exposure through specialised instrument businesses or indirect exposure through larger companies with greater financial resilience.

Progress in Stereology Can Also Create Losers

Technological progress does not raise the value of every company already participating in the field.

A vendor selling manual counting software may face pressure from AI-assisted platforms. A microscope business that cannot integrate automated acquisition and analysis can lose customers to more complete systems. Service providers dependent on labour-intensive pathology may see margins pressured if competitors automate faster.

Older installed equipment can also lose value if new workflows require digital cameras, motorised stages, high-throughput scanning or larger data-processing capacity.

At the same time, customers can benefit. Pharmaceutical companies may pay less per analysis or receive results faster. Academic laboratories may extract more information from the same research budget.

This is why investors should separate industry growth from company advantage. A growing scientific market can still produce poor stock returns for companies that lose share or spend too heavily trying to keep up.

Technical progress changes the distribution of profits. It does not guarantee that all participants receive more of them.

Stereology Is Becoming Part of a Larger Quantitative Biology Stack

The long-term direction is away from stereology as a specialist researcher manually counting structures through a microscope and toward integrated quantitative imaging.

Sampling principles remain relevant. Researchers still need to avoid bias, define reference volumes correctly and understand what their images actually represent. What changes is how those principles are implemented. Motorised microscopes can sample automatically. Three dimensional imaging can collect richer volumes. AI can classify cells. Cloud systems can store slides and allow researchers in different locations to examine the same tissue.

That progression broadens the commercial opportunity from a narrow scientific method into a stack containing instruments, reagents, sample preparation, image storage, analytical software and research services.

Public companies including Danaher, Thermo Fisher, Bruker, Charles River and Roche participate in different parts of that stack. None should be considered a pure stereology investment. Their exposure comes from the larger movement toward quantitative microscopy, pathology and data-driven biology.

For investors, that is the useful frame. Stereology is not the market. It is one of the scientific foundations helping the market move from looking at tissue toward measuring it.

What Stereology Progress Means for Investors

The investment case surrounding stereology is therefore less about discovering one breakthrough technique and more about following the industrialisation of quantitative imaging.

Manual stereology established ways to estimate cell number, volume, surface and other three dimensional properties without relying on misleading two dimensional counts. Automation can reduce the labour required. Three dimensional microscopy increases the amount of biological information available. AI can accelerate segmentation and classification. Digital pathology makes tissue data easier to share, archive and analyse at scale.

Each stage changes where companies can earn money.

Microscope manufacturers can sell more capable systems. Software vendors can monetise analysis and workflow tools. CROs can process studies faster. Diagnostics companies can combine scanning with biomarker algorithms. Drug developers can receive more reproducible preclinical evidence, although the effect on their eventual drug economics remains indirect.

The investor’s job is to connect the scientific development with a financial mechanism. Does it increase instrument demand? Raise recurring software revenue? Improve laboratory throughput? Strengthen customer retention? Reduce research costs? Create a regulatory barrier that protects established vendors?

If that connection cannot be demonstrated, the science may be fascinating without being financially material.

Stereology can therefore be useful to investors even though it will rarely appear as a line item in a financial statement. It helps explain why quantitative imaging, digital pathology and automated research workflows are becoming more valuable.

The better investment question is not “Which stock is a stereology stock?” It is “Which companies are turning better biological measurement into revenue, efficiency or a defensible position that can matter to shareholders?”